David Marks, MD, PhD from University Hospitals Bristol NHS Foundation Trust, Bristol, UK, describes his acute lymphoblastic leukemia (ALL) highlights from the European Society of Hematology congress in Madrid, Spain. He discusses two positive randomised trials demonstrating the effect of inotuzumab and blinatumomab in relapsed/refractory ALL patients. He also talks about CAR-T cells and the fact that there are some concerns about the effects these agents will have on patients.

свернуть